No, but these vaccines, and I think it’s really important that because melanoma in Sweden is not a problem because we have, but in many countries, it’s actually a big problem that the primary tumour is gone somewhere and it’s not handled. And we have to build repositories, basically, and think that for every primary melanoma we remove, we have the kind of quality match that. So we have and the possibility to utilise it later on when patients maybe recur or needs to be treated adjuvantly at higher risks...
No, but these vaccines, and I think it’s really important that because melanoma in Sweden is not a problem because we have, but in many countries, it’s actually a big problem that the primary tumour is gone somewhere and it’s not handled. And we have to build repositories, basically, and think that for every primary melanoma we remove, we have the kind of quality match that. So we have and the possibility to utilise it later on when patients maybe recur or needs to be treated adjuvantly at higher risks. So it will definitely be. So surgeons are still needed and surgeons are very much needed in building up this multidisciplinary teamwork to make this feasible, because that is an interesting question with these new vaccines that we see. How will it be adopted and how will it actually in real world work? It’s one thing to do it in a very, what do you say, limited trial with all of the trial power you have in it. But to do within clinical reality throughout the world, it will be very interesting. And I think surgeons should be heavily involved in doing that as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.